Forest, Daiichi Partner To Promote Hypertension Combo Azor Upon Approval
This article was originally published in PharmAsia News
Executive Summary
Forest Laboratories and Daiichi Sankyo are building upon an ongoing collaboration for Benicar and Benicar HCT with the signing of a new deal to co-promote the fixed-dose antihypertensive Azor, whose approval is anticipated in September. The companies announced the signing of a letter of intent to enter into a collaboration Aug. 21
You may also be interested in...
Forest Ends Daiichi Azor Deal To Focus On Its Own Products
Forest Laboratories regained the equivalent of 500 sales reps by terminating a three-year co-promotion deal with Daiichi Sankyo for the fixed-dose antihypertensive Azor, the company announced May 12.
Forest Ends Daiichi Azor Deal To Focus On Its Own Products
Forest Laboratories regained the equivalent of 500 sales reps by terminating a three-year co-promotion deal with Daiichi Sankyo for the fixed-dose antihypertensive Azor, the company announced May 12.
Daiichi Sankyo U.S. CEO Joe Pieroni: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Exec discusses the anti-platelet drug prasugrel that Daiichi is developing with Lilly, Daiichi’s planned sales force expansion, and his views on partnering in the U.S. and Asia.